Key facts
- This page summarizes Jason Haas's Form 4 filing for Odyssey Therapeutics, Inc. (ODTX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 11 May 2026, 20:32.
Jason Haas - 08 May 2026 Form 4 Insider Report for Odyssey Therapeutics, Inc. (ODTX)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- ODTX
- Reported as of
- 08 May 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 11 May 2026, 20:32:41 UTC
- Prior SEC filing
- 07 May 2026
- Next SEC filing
- 09 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jolie M. Siegel, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jason Haas filed Form 4 for Odyssey Therapeutics, Inc. (ODTX) on 11 May 2026.
Change
- Previous filing in this sequence was filed on 07 May 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001883821
Primary reporting owner
Haas Jason
- Relationship
- Chief Financial Officer
- Address
- C/O ODYSSEY THERAPEUTICS, INC., 51 SLEEPER STREET, SUITE 800, BOSTON
- Signature
- /s/ Jolie M. Siegel, Attorney-in-Fact
- Signature date
- 11 May 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ODTX
transaction
Common Stock
Purchase
- Transaction value
- Shares
- +1,000
- Change %
- +1.6%
- Price
- $20.00*
- Shares after
- 62,908
- Date
- 08 May 2026
- Ownership
- Direct
* marks a reported price that did not pass the local price check.